UCM-1306
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM) . UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) [1].
Product Specifications
CAS Number
2258608-78-3
UNSPSC
12352005
Target
Dopamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ucm-1306.html
Purity
99.61
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=C(C2=C(OCF)C=CC=C2)C=C1)(C)=N
Molecular Formula
C14H14FNO2S
Molecular Weight
279.33
References & Citations
[1]García-Cárceles J, et, al. 2- (Fluoromethoxy) -4'- (S-methanesulfonimidoyl) -1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease. J Med Chem. 2022 Sep 22;65 (18) :12256-12272.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC402540-100 1x 100 µL
SOX4 (Master Regulator of Epithelial-Mesenchymal Transition) (SOX4/2540), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details